IXA4, the most selective IRE1α-XBP1 activator, can promote the degradation of Alzheimer’s disease-associated amyloid precursor protein (APP) mutants, prevent APP-associated mitochondrial dysfunction, and remodel obesity-induced metabolic dysfunction [50]. Here, XBP1 is linked to obesity disorder.